Relmada Therapeutics (NASDAQ:RLMD) Issues Earnings Results, Misses Expectations By $0.04 EPS

Relmada Therapeutics (NASDAQ:RLMD) announced its quarterly earnings data on Tuesday. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04), FiscalAI reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

• Relmada said it remains on track to initiate the phase III RESCUE program for NDV-01 in mid-2026, supported by FDA alignment and a newly completed $160 million private placement.
• The company highlighted strong 12-month phase II NDV-01 data in high-risk NMIBC, including a 95% complete response rate at any time and durable 76% CR at 12 months, with no progression to muscle-invasive disease or radical cystectomy.
• Management emphasized NDV-01’s favorable safety profile and office-friendly delivery, saying it can be administered in under five minutes without a specialized pharmacy, which they believe could support real-world adoption.
• Relmada filed a provisional U.S. patent application for NDV-01 formulations and methods of treatment that, if granted and expanded globally, could extend coverage into 2047 and strengthen commercial exclusivity.
• The company ended Q1 with $234 million in cash and said it expects that runway to fund operations through 2029, including completion of the NDV-01 phase III program, while also preparing a mid-2026 proof-of-concept study for sepranolone in Prader-Willi syndrome.

Relmada Therapeutics Price Performance

RLMD traded up $0.08 during trading on Wednesday, reaching $7.53. 237,795 shares of the stock were exchanged, compared to its average volume of 1,422,393. The company has a market capitalization of $789.30 million, a price-to-earnings ratio of -5.22 and a beta of 0.43. Relmada Therapeutics has a 1 year low of $0.38 and a 1 year high of $8.00. The business’s 50 day moving average price is $6.68 and its two-hundred day moving average price is $4.88.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on RLMD. Mizuho upped their price objective on Relmada Therapeutics from $10.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, March 20th. Zacks Research upgraded shares of Relmada Therapeutics to a “hold” rating in a research report on Tuesday, January 27th. Piper Sandler started coverage on shares of Relmada Therapeutics in a report on Tuesday, March 24th. They issued an “overweight” rating and a $12.00 price target for the company. Leerink Partners upgraded shares of Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 price objective for the company in a research note on Friday, January 23rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Relmada Therapeutics in a report on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $12.00.

Institutional Investors Weigh In On Relmada Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC purchased a new position in Relmada Therapeutics during the 4th quarter valued at about $35,041,000. Squadron Capital Management LLC acquired a new stake in shares of Relmada Therapeutics in the fourth quarter valued at approximately $32,361,000. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Relmada Therapeutics in the fourth quarter valued at approximately $20,624,000. Marshall Wace LLP increased its stake in shares of Relmada Therapeutics by 1,072.4% during the 4th quarter. Marshall Wace LLP now owns 3,189,662 shares of the company’s stock worth $15,406,000 after purchasing an additional 2,917,609 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new position in shares of Relmada Therapeutics during the 4th quarter worth approximately $12,609,000. 45.24% of the stock is currently owned by hedge funds and other institutional investors.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.